基于生物材料的药物输送:评估脂质体Vyxeos的安全概况
Zhicheng Liu1, Zhuo Fu2, Yahui Liu3
1Department of Gastric and Colorectal Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, Jilin Province, China.
Drug delivery
|May 2, 2025
概括
在高风险急性髓性白血病 (AML) 中使用Vyxeos (cytarabine和daunorubicin脂酶体) 与显著的血液学,传染病和心脏不良事件有关. 密切监测患者是否有这些毒性至关重要.
科学领域:
- 在瘤学瘤学.
- 药物监督 药物监督 药物监督
- 血液学 血液学 血液学
背景情况:
- 维克索斯 (cytarabine和daunorubicin脂质体) 为高风险急性髓性白血病 (AML) 提供了更好的生存率.
- 对Vyxeos的真实安全数据对于全面的患者护理至关重要.
- 了解Vyxeos的不良事件概况指导临床管理.
研究的目的:
- 在现实环境中评估Vyxeos的安全概况.
- 为了识别和量化与Vyxeos治疗相关的不良事件.
- 评估与Vyxeos相关的不良事件的人口和时间模式.
主要方法:
- 从美国FDA不良事件报告系统 (FAERS) (2017年1月至2024年6月) 追溯分析了1,036份Vyxeos报告.
- 对患者人口统计,器官系统类 (SOC) 和首选术语 (PT) 的分析.
- 使用不成比例指标 (ROR,PRR,BCPNN,MGPS) 进行信号检测.
主要成果:
- 血液病 (37.73%),传染病 (28.42%) 和心脏病 (13.22%) 是最常见的疾病.
- 发烧性中性质疏松症 (ROR=92.18),中性质疏松性败血症和真菌性肺炎是常见的,与发烧性中性质疏松症有很强的关联.
- 副作用通常在30天内发生;16.92%导致住院,18.33%导致死亡.
结论:
- 在现实世界AML治疗中,Vyxeos与显著的血液学,传染病和心脏不良事件有关.
- 建议对Vyxeos的患者进行密切监测,感染预防和心脏评估.
- 需要进一步的研究来验证发现并了解毒性机制.
相关概念视频
Drug Delivery: Overview
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...
Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
Modified-Release Drug Delivery Systems: Bioavailability
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...


